Catalog No.
DHC13602
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
IL5, B-cell differentiation factor I, IL-5, T-cell replacing factor, TRF, Eosinophil differentiation factor, Interleukin-5
Concentration
1.44 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05113
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SB-240563, CAS: 196078-29-2
Clone ID
Mepolizumab
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis, PMID: 28514601
Mepolizumab treatment in patients with severe eosinophilic asthma, PMID: 25199059
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma, PMID: 32034960
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, PMID: 22901886
Mepolizumab effectiveness and identification of super-responders in severe asthma, PMID: 32139455
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma, PMID: 25199060
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease, PMID: 28893134
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial, PMID: 32956756
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis, PMID: 32817259
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma, PMID: 30359681
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma, PMID: 31049972
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial, PMID: 28687232
Mepolizumab (Nucala) [Internet], PMID: 28121100
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study, PMID: 31447130
Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome, PMID: 29751154
Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma, PMID: 31502421
The spectrum of therapeutic activity of mepolizumab, PMID: 31424304
Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype, PMID: 31425781
An evaluation of mepolizumab for the treatment of severe asthma, PMID: 31009582
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis, PMID: 31146595
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis, PMID: 30578883
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme, PMID: 32241829
Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma, PMID: 32275980
Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma, PMID: 33300186
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis, PMID: 29637936
Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, PMID: 32401603
Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease, PMID: 31496677
Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases, PMID: 32923277
Mepolizumab: First Global Approval, PMID: 26603873
[CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma], PMID: 30326819
Mepolizumab and exacerbations of refractory eosinophilic asthma, PMID: 19264686
Mepolizumab for the treatment of severe eosinophilic asthma, PMID: 28645995
Mepolizumab: A Review in Eosinophilic Asthma, PMID: 27311938
The safety of mepolizumab for the treatment of asthma, PMID: 28116937
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis, PMID: 21958585
Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations, PMID: 30570418
Role of Biologics in Asthma, PMID: 30525902
Treatment of patients with the hypereosinophilic syndrome with mepolizumab, PMID: 18344568
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial, PMID: 28395936
The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma, PMID: 33486140
Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy, PMID: 32084443
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study, PMID: 27553751
Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PMID: 28933002
Mepolizumab and eosinophil-mediated disease, PMID: 19929788
Mepolizumab-based therapy in asthma: an update, PMID: 26110690
Mepolizumab versus placebo for asthma, PMID: 26214266
Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature, PMID: 32268213
Mepolizumab for Eosinophilic COPD, PMID: 29446292
Mepolizumab for Eosinophilic COPD, PMID: 29446291
Mepolizumab for Eosinophilic COPD, PMID: 29443666
For research use only. Not for human or drug use.
